ʻO ka noiʻi nui ʻana i nā mīkini senescence cellular i alakaʻi i ka hoʻomohala ʻana o FOXO4-DRI, he pūhui senolytic i kapa ʻia ʻo IT-Inhibitor peptide. Hōʻike kēia peptide bioactive i nā waiwai anti-kahiko.
I loko o nā pūnaewele kahiko, ʻo kahi laʻana, Hoʻopili ʻo FOXO4 i p53, ka hana ʻana i kahi paʻakikī i kapa ʻia ʻo FOXO4-p53 aggregates. Ke hana nei kēia paʻakikī ma ke ʻano he mea pale o apoptosis hoʻomaka. No laila, hooloihi keia launa ana i ke ola o cellular senescence a alakaʻi i ko lākou hōʻiliʻili ʻana i ka manawa.
ʻIke ʻia, ʻAʻole kuhikuhi pono ʻo FOXO4-DRI iā FOXO1, FOXO3, aiʻole nā protein p53. aka, pili pono ia me ka pūnaewele paʻa o FOXO4 i loko o ka paʻakikī FOXO4-p53. Hoʻoikaika kēia pilina i ka dissociation o ka paʻakikī, hoopuka p53, a ma laila e hoʻāla hou ai i ka apoptosis i hoʻokomo ʻia i ka p53, ʻoiai e mālama ana i nā cell maʻamau mai nā hopena ʻaoʻao.
Hōʻike kekahi mau hōʻike i ka ikaika o ka FOXO4-DRI i ka pepehi ʻana i nā cell senescent.. Eia kekahi, Hōʻike nā haʻawina e hoʻohuli ʻo FOXO4-DRI i ka emi ʻana o ke kino pili makahiki: hoʻonui ia i ka hoʻomanawanui kino a me ka hana kaʻa, hoʻihoʻi i ka hana renal a me ka ulu lauoho, a pēlā e hoʻolohi ai i ka pohō o ka ʻiʻo pili makahiki. ʻo kahi laʻana, Hōʻike maopopo nā kiʻi ʻiole kahiko i kēia mau pōmaikaʻi. Eia hou, FOXO4-DRI hoemi ʻaʻa mau a me ka pōʻino o ke kino i ka microenvironment post-chemotherapy, no laila e hoʻomaikaʻi ai i ka maikaʻi o ke ola a me ka hāpai ʻana i ke olakino lōʻihi i nā maʻi maʻi maʻi.
Kaʻina
H-D-Leu-D-Thr-D-Leu-D-Arg-D-Lys-D-Glu-D-Pro-D-Ala-D-Ser-D-Glu-D-Ile-D- Ala-D-Gln-D-Ser-D-Ile-D-Leu-D-Glu-D-Ala-D-Tyr-D-Ser-D-Gln-D-Asn-D-Gly- D-Trp-D-Ala-D-Asn-D-Arg-D-Arg-D-Ser-D-Gly-D-Gly-D-Lys-D-Arg-D-Pro-D-Pr o-D-Pro-D-Arg-D-Arg-D-Arg-D-Gln-D-Arg-D-Arg-D-Lys-D-Lys-D-Arg-D-Gly-OH
Helu CAS
2460055-10-9
ʻĀpana Molekala
C228H388N86O64
Kaumaha Molekala
5358.05
Noiʻi No Foxo4-dri Pono
1.Hookomo koho o Senescent Cell Apoptosis
ʻO ka hana mua o FOXO4-DRI e pili ana i ka hoʻoulu ʻia ʻana o ka make cell programmed i nā cell senescent.. Eia, Ke hana nei ka p53 ma ke ʻano he trans-activating factor no nā genes pro-apoptotic, ka hoʻoulu ʻana i ka apoptosis. Eia naʻe, ma lalo o nā kūlana physiological maʻamau, ka FOXO4-p53 complex e hoʻopio i kēia hana apoptotic.
Ma ka hoʻokūkū ʻana no ka paʻa p53, Hoʻopilikia ka FOXO4-DRI i ka pilina FOXO4-p53. Hoʻomaka kēia pilikia i ke ala apoptosis intrinsic i nā cell senescent.
I nā ʻiole kahiko, ʻO ka mālama ʻana me FOXO4-DRI i alakaʻi i ka ulu hou ʻana o ka lauoho e like me nā ʻiole waena a me ka hoʻomaikaʻi nui ʻana i ka hana kaʻa..
2.Ka maikaʻi o ke ola no nā maʻi maʻi maʻi maʻi
Ke ʻimi nei nā mea noiʻi iā FOXO4-DRI ma ke ʻano he lāʻau adjuvant hiki ke hoʻomaikaʻi i ka maikaʻi o ke ola no nā poʻe maʻi maʻi maʻi ma hope ka lāʻau lapaʻau. ʻOiai e pili ana ka nui o nā mea anticancer nā pūnaeʻa tumora, hana pū lākou i ka hōʻeha kikoʻī ʻole i nā cell maʻamau, hoʻonui i ke kaumaha o ka senescence i hoʻokomo ʻia i ka therapy(TIS).
Hōʻoia nā haʻawina nui e hiki i ka FOXO4-DRI ke hoʻopau pono i nā cell senescent kuʻuna a me ka mālama ʻana., hoʻomaikaʻi i ka chemotherapy-induced maʻi palupalu. ʻo kahi laʻana, Ua hōʻike ʻia kahi haʻawina ma Cell i ka hoʻomaikaʻi ʻana a me ke ola ʻana i nā ʻiole i mālama ʻia i ka chemotherapy. Ke hōʻike nei kēia mau ʻike i ka hiki ke hoʻoikaika kino adjuvant o FOXO4-DRI i ka oncology.
3.ʻO ka hoʻomaikaʻi ʻana i ka maʻi maʻi ate
In NASH(ʻO ka steatohepatitis no ka waiʻona) nā maʻi, ʻulaʻula hōʻiliʻili i loko o ke ake a huna i nā molekala pro-inflammatory a me pro-fibrotic ma o ka phenotype huna e pili ana i ka senescence (SASP), hoʻokele maʻi holomua. Ua ʻike ʻia nā haʻawina e hoʻohana ana i ka ʻiole NASH model ua hoʻopau ʻo FOXO4-DRI i kēia mau pūnaewele hepatic senescent, ke kāohi nei i ka hana SASP ma kona kumu.
4.Lapaʻau ʻana i nā ʻiole me ka Bleomycin-Induced Pulmonary Fibrosis
Hoʻomaka ka FOXO4-DRI i ka wehe ʻana i ka nuklea p53 a me ka wehe ʻana o ka paʻakikī FOXO4-p53. I nā ʻiole i hoʻokomo ʻia i ka bleomycin, lapaʻau me FOXO4-DRI emi pae o Collagen, ʻano I, alpha 1 (Kol1a1) a me ka α-SMA ma nā ʻiʻo māmā. Hōʻike kēia hōʻemi i ka emi ʻana o ka hana ʻana o ka matrix extracellular a me ka pale ʻana o myofibroblast hoʻoulu ʻana.
ʻOiai ʻaʻole i wehewehe piha ka haʻawina i ke ala pololei o ka launa pū ʻana o FOXO4-DRI me p53., ua hōʻike maikaʻi ʻia ka pale ʻana i ka fibrosis, e hōʻike ana i kahi hoʻolālā therapeutic kūpono no idiopathic pulmonary fibrosis (IPF).
5.Hoʻohaʻahaʻa i ka makahiki Hypogonadism (ʻAʻohe Testosterone)
ʻO ka hypogonadism hoʻomaka mua o ke kāne he maʻi maʻi e pili ana i ka ʻelemakule e hōʻino ana i nā pūnaewele Leydig kahiko. Hiki ke hoʻomaʻemaʻe i ka hana o ka ʻiʻo i ka hoʻomaʻemaʻe ʻana i kēia mau senescent cell. Hōʻike nā haʻawina e hana pono ana ʻo FOXO4-DRI i ka testicular kanaka Leydig cell. ʻO ka lawelawe ʻana i nā ʻiole kahiko i hoʻomaikaʻi i ka microenvironment testicular, pale ana i ka nele o ka testosterone pili makahiki. A 2021 Ua hōʻike ka haʻawina i ka piʻi nui ʻana o nā pae testosterone serum i nā ʻiole kahiko i mālama ʻia.
ʻO ka hana i manaʻo ʻia e pili ana i ka hoʻopau ʻana i ka localization nuklea p53 a me ka dissociation o ka paʻakikī FOXO4-p53., ka hopena i ka apoptosis cell senescent. Hōʻike kēia mau hopena i kahi ala lapaʻau kūpono no ka mālama ʻana i ka hōʻemi testosterone pili makahiki.
COA
HPLC
MS





